• Japanese
  • Korean
  • Chinese
Cover Image

Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Abstract

This report will excel your competitive awareness and decrease your decision making time in managing breast cancer drug development. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

This report comprises defined and up to date development strategies for 470 breast cancer drugs within the portfolio of 247 companies world-wide, from Ceased to Marketed. The report extensively analyses their 234 identified drug targets, organized into 223 drug target strategies, and assesses them in breast cancer.

BioSeeker has applied its unique drug assessment methodology to stratify the breast cancer drug pipeline and discern the level of competition in fine detail.

Major Findings from this report:

  • The identified competitive landscape of breast cancer drugs is split between the approximately one third which have unique drug target strategies and the other two thirds which have head-to-head target competing drugs in 61 different clusters. The latter has a competing ratio which is almost two and a half times higher than the comparable average of the breast cancer drugs in general.
  • Nine out of every ten drug target strategies in Phase II and three out of every four in Phase III development are new to breast cancer drugs.
  • The greatest number of new target strategies are found in Phase II (35%) and Preclinical (17%) development.
  • Small molecules, Antibodies and Reformulated drugs are the dominating compound strategies of breast cancer drugs, which represent almost 80% of the entire pipeline.
  • Besides Reformulated drugs, it is Cell therapies, Peptides and Antibodiesbased breast cancer drugs that have the highest cross-over of drug target strategies with other compound strategies.
  • The highest number of described drug target strategies of breast cancer drugs belongs to Pfizer, AstraZeneca and Hoffmann-La Roche.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

  • Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
  • Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
  • Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
  • Supporting development of integrative molecule, pathway and disease area strategies
  • Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any breast cancer drug to ensure that the optimal market conditions exist by the time the product is commercialized.

Table of Contents

1. Executive Summary

2. About Cancer Highlights™

  • 2.1. Cancer Focus Areas
  • 2.2. Subscribe Today and Start Saving
    • 2.2.1. Type of License
  • 2.3. Additional Information
  • 2.4. BioSeeker Group's Oncology Team

3. Methodology

  • 3.1. Cancer Highlights'™ Five Pillar Drug Assessment

4. Table of Contents

  • 4.1. List of Figures
  • 4.2. List of Tables

5. Introduction

  • 5.1. The Scope of this Report
  • 5.2. Definitions
  • 5.3. Abbreviations

6. Consider the Therapeutic Target Among Breast Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment

  • 6.1. Drug Repositioning in Oncology
  • 6.2. Introduction to Targets of Breast Cancer Drugs
    • 6.2.1. Acid Phosphatase Activity Targets
    • 6.2.2. Auxiliary Transport Protein Activity Targets
    • 6.2.3. Catalytic Activity Targets
    • 6.2.4. Cell Adhesion Molecule Activity Targets
    • 6.2.5. Chaperone Activity Targets
    • 6.2.6. Chemokine Activity Targets
    • 6.2.7. Complement Activity Targets
    • 6.2.8. Cysteine-type Peptidase Activity Targets
    • 6.2.9. Cytokine Activity Targets
    • 6.2.10. DNA Binding Targets
    • 6.2.11. DNA Repair Protein Targets
    • 6.2.12. DNA Topoisomerase Activity Targets
    • 6.2.13. DNA-directed DNA Polymerase Activity Targets
    • 6.2.14. Extracellular Ligand-gated Ion Channel Activity Targets
    • 6.2.15. Extracellular Matrix Structural Constituent Targets
    • 6.2.16. G-protein Coupled Receptor Activity Targets
    • 6.2.17. Glutathione Transferase Activity Targets
    • 6.2.18. Growth Factor Activity Targets
    • 6.2.19. Growth Factor Binding Targets
    • 6.2.20. Hormone Activity Targets
    • 6.2.21. Intracellular Ligand-gated Ion Channel Activity Targets
    • 6.2.22. Ion Channel Activity Targets
    • 6.2.23. Isomerase Activity Targets
    • 6.2.24. Kinase Activity Targets
    • 6.2.25. Kinase Binding Targets
    • 6.2.26. Kinase Regulator Activity Targets
    • 6.2.27. Ligand-dependent Nuclear Receptor Activity Targets
    • 6.2.28. Ligase Activity Targets
    • 6.2.29. Lipid Kinase Activity Targets
    • 6.2.30. Lipid Phosphatase Activity Targets
    • 6.2.31. Metallopeptidase Activity Targets
    • 6.2.32. Molecular Function Unknown Targets
    • 6.2.33. Motor Activity Targets
    • 6.2.34. Oxidoreductase Activity Targets
    • 6.2.35. Peptidase Activity Targets
    • 6.2.36. Peptide Hormone Targets
    • 6.2.37. Peroxidase Activity Targets
    • 6.2.38. Phosphoric Diester Hydrolase Activity Targets
    • 6.2.39. Protein Binding Targets
    • 6.2.40. Protein Serine/Threonine Kinase Activity Targets
    • 6.2.41. Protein Threonine/Tyrosine Kinase Activity Targets
    • 6.2.42. Protein-tyrosine Kinase Activity Targets
    • 6.2.43. Receptor Activity Targets
    • 6.2.44. Receptor Binding Targets
    • 6.2.45. Receptor Signaling Complex Scaffold Activity Targets
    • 6.2.46. Receptor Signaling Protein Serine/Threonine Kinase Activity Targets
    • 6.2.47. RNA Binding Targets
    • 6.2.48. RNA-directed DNA Polymerase Activity Targets
    • 6.2.49. Serine-type Peptidase Activity Targets
    • 6.2.50. Structural Constituent of Cytoskeleton Targets
    • 6.2.51. Structural Molecule Activity Targets
    • 6.2.52. Superoxide Dismutase Activity Targets
    • 6.2.53. T Cell Receptor Activity Targets
    • 6.2.54. Transcription Factor Activity Targets
    • 6.2.55. Transcription Regulator Activity Targets
    • 6.2.56. Transferase Activity Targets
    • 6.2.57. Translation Regulator Activity Targets
    • 6.2.58. Transmembrane Receptor Activity Targets
    • 6.2.59. Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
    • 6.2.60. Transporter Activity Targets
    • 6.2.61. Voltage-gated Ion Channel Activity Targets
    • 6.2.62. Other Targets
  • 6.3. Mutation Profiles of Breast Cancer Drug Targets
    • 6.3.1. Targets of Breast Cancer Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
  • 6.4. Breast Cancer Therapeutics is Stimulated by Available Structure Data on Targets
  • 6.5. Target-Target Interactions among Identified Targets of Breast Cancer Drugs
  • 6.6. The Drug-Target Competitive Landscape
  • 6.7. Protein Expression Levels of Identified Targets of Breast Cancer Drugs
  • 6.8. Pathway Assessment of Breast Cancer Drugs
    • 6.8.1. Tools for Analysis of Cancer Pathways
    • 6.8.2. Pathway Assessment

7. Emerging New Products to Established Ones: Drug Target Strategies of Breast Cancer Drugs by their Highest Stage of Development

  • 7.1. Marketed: New and Unique Drug Target Strategies of Breast Cancer Drugs
  • 7.2. Phase III Clinical Development: New and Unique Drug Target Strategies of Breast Cancer Drugs
  • 7.3. Phase II Clinical Development: New and Unique Drug Target Strategies of Breast Cancer Drugs
  • 7.4. Phase I Clinical Development: New and Unique Drug Target Strategies of Breast Cancer Drugs
  • 7.5. Preclinical Development: New and Unique Drug Target Strategies of Breast Cancer Drugs
  • 7.6. Drug Target Strategies of Suspended or Terminated Breast Cancer Drugs
  • 7.7. Target Strategy Development Profiles of Breast Cancer Drugs
    • 7.7.1. Marketed
    • 7.7.2. Phase III
    • 7.7.3. Phase II
    • 7.7.4. Phase I
    • 7.7.5. Preclinical
    • 7.7.6. No Data
    • 7.7.7. Suspended
    • 7.7.8. Ceased
  • 7.8. The Competition Through Close Mechanistic Approximation of Breast Cancer Drugs

8. Compound Strategies at Work: Competitive Benchmarking of Breast Cancer Drugs by Compound Strategy

  • 8.1. Small Molecules
    • 8.1.1. Background
    • 8.1.2. Target Strategies of Small Molecule Drugs
  • 8.2. Peptide & Protein Drugs
    • 8.2.1. Background
    • 8.2.2. Target Strategies of Peptide and Protein Drugs
  • 8.3. Antibodies
    • 8.3.1. Background
    • 8.3.2. Target Strategies of Antibody Drugs
  • 8.4. Nucleic Acid Therapies
    • 8.4.1. Background
    • 8.4.2. Target Strategies of Nucleic Acid Drugs
  • 8.5. Cell & Gene Therapy
    • 8.5.1. Background
    • 8.5.2. Target Strategies of Cell and Gene Therapy Drugs
  • 8.6. Drug Delivery and Nanotechnology
    • 8.6.1. Background
    • 8.6.2. Target Strategies of Reformulated Drugs
  • 8.7. Compound Strategies based on Sub-Cellular Localization of Drug Targets

9. Pipeline and Portfolio Planning: Competitive Benchmarking of the Breast Cancer Drug Pipeline by Investigator

  • 9.1. Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change
  • 9.2. Company Facts and Ranking
  • 9.3. Competitive Fall-Out Assessment
  • 9.4. A&G Pharmaceutical
  • 9.5. Abbott
  • 9.6. Abiogen
  • 9.7. Access
  • 9.8. Adherex
  • 9.9. Advanomics
  • 9.10. Advaxis
  • 9.11. AEgera
  • 9.12. AEterna Zentaris
  • 9.13. Affibody
  • 9.14. Affimed Therapeutics
  • 9.15. Alchemia
  • 9.16. Alethia Biotherapeutics
  • 9.17. Allos Therapeutics
  • 9.18. Alnis Biosciences
  • 9.19. AlphaVax
  • 9.20. Alseres Pharmaceuticals
  • 9.21. Amgen
  • 9.22. AngioChem
  • 9.23. Antisoma
  • 9.24. Aphios
  • 9.25. Ariad
  • 9.26. ArQule
  • 9.27. Array BioPharma
  • 9.28. Ascend Therapeutics
  • 9.29. Ascepion Pharmaceuticals
  • 9.30. Astellas
  • 9.31. Astex Pharmaceuticals
  • 9.32. AstraZeneca
  • 9.33. Attenuon
  • 9.34. AVI BioPharma
  • 9.35. Basilea Pharmaceutica
  • 9.36. Bavarian Nordic
  • 9.37. Bayer
  • 9.38. Beta Pharma
  • 9.39. Betagenon
  • 9.40. Biogen Idec
  • 9.41. BioMarin
  • 9.42. Bionovo
  • 9.43. BioSante
  • 9.44. Biotecnol
  • 9.45. Boehringer Ingelheim
  • 9.46. Bristol-Myers Squibb
  • 9.47. BTG
  • 9.48. Callisto Pharmaceuticals
  • 9.49. Cancer Research Technology
  • 9.50. Cel-Sci
  • 9.51. Celgene
  • 9.52. Cell Therapeutics
  • 9.53. Celldex Therapeutics
  • 9.54. Celltrion
  • 9.55. Celsion
  • 9.56. Celtic Pharma
  • 9.57. Center of Molecular Immunology
  • 9.58. Chemokine Therapeutics
  • 9.59. Chiesi
  • 9.60. Chong Kun Dang
  • 9.61. CompleGen
  • 9.62. Curis
  • 9.63. Cyclacel
  • 9.64. Cylene Pharmaceuticals
  • 9.65. Cynvec
  • 9.66. CytImmune Sciences
  • 9.67. Cytokinetics
  • 9.68. CytRx
  • 9.69. Daiichi Sankyo
  • 9.70. Dainippon Sumitomo Pharma
  • 9.71. Debiopharm
  • 9.72. Dendreon
  • 9.73. Domainex
  • 9.74. Dong-A
  • 9.75. Dongkook Pharm
  • 9.76. Douglas
  • 9.77. ECI
  • 9.78. Eisai
  • 9.79. Elara Pharmaceuticals
  • 9.80. ElexoPharm
  • 9.81. Eli Lilly
  • 9.82. Endoceutics
  • 9.83. Enkam Pharmaceuticals
  • 9.84. EntreMed
  • 9.85. Enzon
  • 9.86. Epeius Biotechnologies
  • 9.87. EpiCept
  • 9.88. Epizyme
  • 9.89. Esperance Pharmaceuticals
  • 9.90. Etubics
  • 9.91. Eucodis
  • 9.92. Exelixis
  • 9.93. Expression Drug Designs
  • 9.94. Formula Pharmaceuticals
  • 9.95. Fresenius
  • 9.96. Galectin Therapeutics
  • 9.97. Galena Biopharma
  • 9.98. Genentech
  • 9.99. Generex
  • 9.100. Genmab
  • 9.101. Genta
  • 9.102. GenVec
  • 9.103. Geron
  • 9.104. Gilead Sciences
  • 9.105. GlaxoSmithKline
  • 9.106. GlyTag
  • 9.107. Got-a-Gene
  • 9.108. Gradalis
  • 9.109. Harbor BioSciences
  • 9.110. Heidelberg Pharma
  • 9.111. Hoffmann-La Roche
  • 9.112. Hospira
  • 9.113. Idera Pharmaceuticals
  • 9.114. Immunocore
  • 9.115. ImmunoGen
  • 9.116. Immunomedics
  • 9.117. ImmuPharma
  • 9.118. Immutep
  • 9.119. Incyte Corporation
  • 9.120. Inex
  • 9.121. Infinity Pharmaceuticals
  • 9.122. Innate Pharma
  • 9.123. InNexus Biotechnology
  • 9.124. Inovio
  • 9.125. Insmed
  • 9.126. Insys Therapeutics
  • 9.127. Intarcia Therapeutics
  • 9.128. Intezyne Technologies
  • 9.129. Intradigm
  • 9.130. Introgen Therapeutics
  • 9.131. Ipsen
  • 9.132. Isis Pharmaceuticals
  • 9.133. Jina Pharmaceuticals
  • 9.134. Johnson & Johnson
  • 9.135. Kiadis
  • 9.136. Kinex
  • 9.137. Kyowa Hakko Kirin
  • 9.138. Leo
  • 9.139. Ligand
  • 9.140. Lorus Therapeutics
  • 9.141. MacroGenics
  • 9.142. Marillion Pharmaceuticals
  • 9.143. Marina Biotech
  • 9.144. Meda
  • 9.145 Medarex
  • 9.146. MediGene
  • 9.147. MedImmune
  • 9.148. Mediolanum
  • 9.149. Menarini
  • 9.150. Merck & Co
  • 9.151. Merck KGaA
  • 9.152. Merrimack
  • 9.153. MetaMol Theranostics
  • 9.154. Mologen
  • 9.155. Nektar Therapeutics
  • 9.156. Nemod Biotherapeutics
  • 9.157. Neurocrine Biosciences
  • 9.158. NexGenix Pharmaceuticals
  • 9.159. Nidus Laboratories
  • 9.160. NIH - The US National Institute of Health
  • 9.161. Nimbus Discovery
  • 9.162. Nippon Kayaku
  • 9.163. Non-industrial Source
  • 9.164. Novartis
  • 9.165. Novogen
  • 9.166. Oasmia
  • 9.167. OncoGenex Pharmaceuticals
  • 9.168. Oncolix
  • 9.169. OncoMune
  • 9.170. Onconova
  • 9.171. Oncothyreon
  • 9.172. Oncozyme Pharma
  • 9.173. Orion Pharma
  • 9.174. OSI Pharmaceuticals
  • 9.175. Oxford BioMedica
  • 9.176. Pacific Biotech
  • 9.177. Paladin Labs
  • 9.178. PanaGin
  • 9.179. Pantarhei Bioscience
  • 9.180. Peregrine Pharmaceuticals
  • 9.181. Pfizer
  • 9.182. Pharmacyclics
  • 9.183. PharmaGap
  • 9.184. PharmaMar
  • 9.185. Pharmexa
  • 9.186. PheneX
  • 9.187. Philogen
  • 9.188. Pierre Fabre
  • 9.189. Piramal
  • 9.190. ProStrakan
  • 9.191. PTC Therapeutics
  • 9.192. R&R
  • 9.193. Radient Pharmaceuticals
  • 9.194. Raptor Pharmaceutical
  • 9.195. Receptor BioLogix
  • 9.196. Regeneron
  • 9.197. Regulon
  • 9.198. RESprotect
  • 9.199. Rigel
  • 9.200. Samyang
  • 9.201. Sanofi
  • 9.202. Santaris Pharma
  • 9.203. Sareum
  • 9.204. Savient Pharmaceuticals
  • 9.205. Schering-Plough
  • 9.206. SEEK
  • 9.207. Selvita
  • 9.208. Semafore Pharmaceuticals
  • 9.209. Shenogen
  • 9.210. Sigma-Tau
  • 9.211. Sirnaomics
  • 9.212. SRI International
  • 9.213. Sun Pharma Advanced Research
  • 9.214. Supratek Pharma
  • 9.215. Synageva BioPharma
  • 9.216. Synta Pharmaceuticals
  • 9.217. Taiho
  • 9.218. Taiwan Liposome Company
  • 9.219. Takeda
  • 9.220. Tapestry Pharmaceuticals
  • 9.221. TapImmune
  • 9.222. Targa Therapeutics
  • 9.223. Tau Therapeutics
  • 9.224. Taxolog
  • 9.225. Telik
  • 9.226. Teva
  • 9.227. Thallion Pharmaceuticals
  • 9.228. Therion Biologics
  • 9.229. to-BBB
  • 9.230. TopoTarget
  • 9.231. Tragara Pharmaceuticals
  • 9.232. Transgene
  • 9.233. Trion Pharma
  • 9.234. Vaccinex
  • 9.235. Vaxon Biotech
  • 9.236. Verastem
  • 9.237. Vernalis
  • 9.238. Vical
  • 9.239. Vion Pharmaceuticals
  • 9.240. VioQuest
  • 9.241. ViroMed
  • 9.242. ViroTarg
  • 9.243. Wilex
  • 9.244. Wyeth
  • 9.245. Xerion
  • 9.246. Xoma
  • 9.247. Yakult Honsha
  • 9.248. YM BioSciences
  • 9.249. Zensun
  • 9.250. Zydus Cadila

10. Disclaimer

11. Drug Index

12. Company Index

List of Figures

  • Figure 1: Visualization of Target-Target Interactions among Targets of Breast Cancer Drugs
  • Figure 2: The Drug-Target Competitive Landscape of Breast Cancer Drugs - Large Cluster
  • Figure 3: The Drug-Target Competitive Landscape Breast Cancer Drugs - Smaller Clusters
  • Figure 4: Head-to-Head Targeting Competitive Landscape of Breast Cancer Drugs - Larger Clusters
  • Figure 5: Head-to-Head Targeting Competitive Landscape of Breast Cancer Drugs - Smaller Clusters
  • Figure 6: Distribution of Compound Strategies among Breast Cancer Drugs
  • Figure 7: Primary Sub-cellular Localization of Drug Targets
  • Figure 8: Number of Companies per Ranking Level

List of Tables

  • Table 1: Cancer Highlights'™ Five Pillar Drug Assessment
  • Table 2: Breakdown of the Included Breast Cancer Drug Pipeline by Stage of Development
  • Table 3: Head to Head Target Competition among Breast Cancer Drugs
  • Table 4: Overview of Drug Target Strategy Themes
  • Table 5: Terminally Ceased Targets of Breast Cancer Drugs
  • Table 6: Official Gene Symbol to Target Profle
  • Table 7: Mutation Frequencies of Breast Cancer Drug Targets
  • Table 8: Identity of Drug Targets with Available Biological Structures
  • Table 9: Number of Target-Target Interactions among Targets of Breast Cancer Drugs
  • Table 10: Available Protein Expression Profiles of Breast Cancer Drug Targets
  • Table 11: Pathway Summary
  • Table 12: Drug Targets without any Identified Assigned Pathways
  • Table 13: Pathway Profiles According to BioCarta of Breast Cancer Drug Targets
  • Table 14: Pathway Profiles According to KEGG of Breast Cancer Drug Targets
  • Table 15: Pathway Profiles According to NetPath of Breast Cancer Drug Targets
  • Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness
  • Table 17: Top Competitive Target Strategies of Breast Cancer Drugs
  • Table 18: New and Unique Target Strategies of Marketed Breast Cancer Drugs
  • Table 19: The Competition Through Close Mechanistic Approximation Between Breast Cancer Drugs Being Marketed
  • Table 20: New and Unique Target Strategies in Phase III Clinical Development of Breast Cancer Drugs
  • Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Breast Cancer Drugs
  • Table 22: New and Unique Target Strategies in Phase II Clinical Development of Breast Cancer Drugs
  • Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Breast Cancer Drugs
  • Table 24: New and Unique Target Strategies in Phase I Clinical Development of Breast Cancer Drugs
  • Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Breast Cancer Drugs
  • Table 26: New and Unique Target Strategies in Preclinical Development of Breast Cancer Drugs
  • Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Breast Cancer Drugs
  • Table 28: Target Strategies of No Data, Suspended or Terminated Breast Cancer Drugs
  • Table 29: Connecting Target Strategy with Its Profile Identification Number
  • Table 30: The Competition Through Close Mechanistic Approximation Among Breast Cancer Drugs
  • Table 31: Overview of Compound Strategy Competition Among Breast Cancer Drugs
  • Table 32: Overview of the Competitive Landscape of Small Molecule Based Breast Cancer Drugs
  • Table 33: Competitive Comparison of Target Strategies of Small Molecule Breast Cancer Drugs
  • Table 34: Pursued Target Strategies of Small Molecule Drugs Based Breast Cancer Drugs
  • Table 35: Overview of the Competitive Landscape of Peptide Based Breast Cancer Drugs
  • Table 36: Competitive Comparison of Target Strategies of Peptide Based Breast Cancer Drugs
  • Table 37: Pursued Target Strategies of Peptide Based Breast Cancer Drugs
  • Table 38: Overview of the Competitive Landscape of Protein Based Breast Cancer Drugs
  • Table 39: Competitive Comparison of Target Strategies of Protein Based Breast Cancer Drugs
  • Table 40: Pursued Target Strategies of Protein Based Breast Cancer Drugs
  • Table 41: Overview of the Competitive Landscape of Antibody Based Breast Cancer Drugs
  • Table 42: Competitive Comparison of Target Strategies of Antibody Based Breast Cancer Drugs
  • Table 43: Pursued Target Strategies of Antibody Based Breast Cancer Drugs
  • Table 44: Overview of the Competitive Landscape of Nucleic Acid Based Breast Cancer Drugs
  • Table 45: Competitive Comparison of Target Strategies of Nucleic Acid Based Breast Cancer Drugs
  • Table 46: Pursued Target Strategies of Nucleic Acid Based Breast Cancer Drugs
  • Table 47: Potential Forms of Cell Therapy
  • Table 48: Vectors in Gene Therapy
  • Table 49: Overview of the Competitive Landscape of Cell Therapy Based Breast Cancer Drugs
  • Table 50: Competitive Comparison of Target Strategies of Cell Therapy Based Breast Cancer Drugs
  • Table 51: Pursued Target Strategies of Cell Therapy Based Breast Cancer Drugs
  • Table 52: Overview of the Competitive Landscape of Gene Therapy Based Breast Cancer Drugs
  • Table 53: Competitive Comparison of Target Strategies of Gene Therapy Based Breast Cancer Drugs
  • Table 54: Pursued Target Strategies of Gene Therapy Based Breast Cancer Drugs
  • Table 55: Overview of the Competitive Landscape of Reformulated Breast Cancer Drugs
  • Table 56: Competitive Comparison of Target Strategies of Reformulated Breast Cancer Drugs
  • Table 57: Pursued Target Strategies of Reformulated Breast Cancer Drugs
  • Table 58: Compound Strategies based on Sub-Cellular Localization of Breast Cancer Drug Targets
  • Table 59: Competitive Summary by Investigator of Breast Cancer Drug Development
  • Table 60: Summary Table of Corporate Changes in the Competitive Landscape of Breast Cancer Drug Development
  • Table 61: The Worst Ranking and the Highest Populated Level for Each of the 15 Ranking Parameters
  • Table 62: Example of a Competitive Fall-Out Table (Targeting TYMS/Modified)
  • Table 63: A&G Pharmaceutical's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 64: Abbott's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 65: Abiogen's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 66: Access' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 67: Adherex's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 68: Advanomics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 69: Advaxis' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 70: AEgera's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 71: AEterna Zentaris' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 72: Affibody's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 73: Affimed Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 74: Alchemia's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 75: Alethia Biotherapeutics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 76: Allos Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 77: Alnis Biosciences' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 78: AlphaVax's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 79: Alseres Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 80: Amgen's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 81: AngioChem's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 82: Antisoma's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 83: Aphios' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 84: Ariad's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 85: ArQule's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 86: Array BioPharma's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 87: Ascend Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 88: Ascepion Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 89: Astellas' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 90: Astex Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 91: AstraZeneca's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 92: Attenuon's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 93: AVI BioPharma's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 94: Basilea Pharmaceutica's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 95: Bavarian Nordic's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 96: Bayer's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 97: Beta Pharma's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 98: Betagenon's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 99: Biogen Idec's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 100: BioMarin's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 101: Bionovo's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 102: BioSante's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 103: Biotecnol's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 104: Boehringer Ingelheim's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 105: Bristol-Myers Squibb's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 106: BTG's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 107: Callisto Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 108: Cancer Research Technology's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 109: Cel-Sci's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 110: Celgene's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 111: Cell Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 112: Celldex Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 113: Celltrion's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 114: Celsion's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 115: Celtic Pharma's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 116: Center of Molecular Immunology's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 117: Chemokine Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 118: Chiesi's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 119: Chong Kun Dang's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 120: CompleGen's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 121: Curis' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 122: Cyclacel's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 123: Cylene Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 124: Cynvec's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 125: CytImmune Sciences' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 126: Cytokinetics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 127: CytRx's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 128: Daiichi Sankyo's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 129: Dainippon Sumitomo Pharma's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 130: Debiopharm's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 131: Dendreon's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 132: Domainex's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 133: Dong-A's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 134: Dongkook Pharm's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 135: Douglas' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 136: ECI's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 137: Eisai's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 138: Elara Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 139: ElexoPharm's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 140: Eli Lilly's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 141: Endoceutics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 142: Enkam Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 143: EntreMed's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 144: Enzon's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 145: Epeius Biotechnologies' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 146: EpiCept's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 147: Epizyme's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 148: Esperance Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 149: Etubics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 150: Eucodis' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 151: Exelixis' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 152: Expression Drug Designs' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 153: Formula Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 154: Fresenius' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 155: Galectin Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 156: Galena Biopharma's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 157: Genentech's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 158: Generex's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 159: Genmab's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 160: Genta's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 161: GenVec's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 162: Geron's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 163: Gilead Sciences' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 164: GlaxoSmithKline's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 165: GlyTag's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 166: Got-a-Gene's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 167: Gradalis' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 168: Harbor BioSciences' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 169: Heidelberg Pharma's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 170: Hoffmann-La Roche's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 171: Hospira's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 172: Idera Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 173: Immunocore's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 174: ImmunoGen's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 175: Immunomedics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 176: ImmuPharma's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 177: Immutep's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 178: Incyte Corporation's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 179: Inex's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 180: Infinity Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 181: Innate Pharma's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 182: InNexus Biotechnology's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 183: Inovio's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 184: Insmed's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 185: Insys Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 186: Intarcia Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 187: Intezyne Technologies' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 188: Intradigm's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 189: Introgen Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 190: Ipsen's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 191: Isis Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 192: Jina Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 193: Johnson & Johnson's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 194: Kiadis' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 195: Kinex's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 196: Kyowa Hakko Kirin's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 197: Leo's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 198: Ligand's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 199: Lorus Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 200: MacroGenics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 201: Marillion Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 202: Marina Biotech's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 203: Meda's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 204: Medarex's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 205: MediGene's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 206: MedImmune's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 207: Mediolanum's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 208: Menarini's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 209: Merck & Co's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 210: Merck KGaA's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 211: Merrimack's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 212: MetaMol Theranostics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 213: Mologen's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 214: Nektar Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 215: Nemod Biotherapeutics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 216: Neurocrine Biosciences' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 217: NexGenix Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 218: Nidus Laboratories' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 219: NIH's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 220: Nimbus Discovery's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 221: Nippon Kayaku's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 222: Non-industrial source's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 223: Novartis' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 224: Novogen's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 225: Oasmia's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 226: OncoGenex Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 227: Oncolix's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 228: OncoMune's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 229: Onconova's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 230: Oncothyreon's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 231: Oncozyme Pharma's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 232: Orion Pharma's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 233: OSI Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 234: Oxford BioMedica's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 235: Pacific Biotech's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 236: Paladin Labs' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 237: PanaGin's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 238: Pantarhei Bioscience's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 239: Peregrine Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 240: Pfizer's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 241: Pharmacyclics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 242: PharmaGap's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 243: PharmaMar's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 244: Pharmexa's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 245: PheneX's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 246: Philogen's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 247: Pierre Fabre's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 248: Piramal's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 249: ProStrakan's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 250: PTC Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 251: R&R's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 252: Radient Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 253: Raptor Pharmaceutical's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 254: Receptor BioLogix's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 255: Regeneron's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 256: Regulon's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 257: RESprotect's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 258: Rigel's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 259: Samyang's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 260: Sanofi's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 261: Santaris Pharma's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 262: Sareum's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 263: Savient Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 264: Schering-Plough's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 265: SEEK's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 266: Selvita's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 267: Semafore Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 268: Shenogen's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 269: Sigma-Tau's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 270: Sirnaomics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 271: SRI International's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 272: Sun Pharma Advanced Research's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 273: Supratek Pharma's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 274: Synageva BioPharma's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 275: Synta Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 276: Taiho's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 277: Taiwan Liposome Company's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 278: Takeda's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 279: Tapestry Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 280: TapImmune's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 281: Targa Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 282: Tau Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 283: Taxolog's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 284: Telik's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 285: Teva's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 286: Thallion Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 287: Therion Biologics' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 288: to-BBB's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 289: TopoTarget's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 290: Tragara Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 291: Transgene's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 292: Trion Pharma's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 293: Vaccinex's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 294: Vaxon Biotech's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 295: Verastem's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 296: Vernalis' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 297: Vical's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 298: Vion Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 299: VioQuest's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 300: ViroMed's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 301: ViroTarg's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 302: Wilex's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 303: Wyeth's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 304: Xerion's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 305: Xoma's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 306: Yakult Honsha's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 307: YM BioSciences' Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 308: Zensun's Included Breast Cancer Drugs and Competitive Fall-Out
  • Table 309: Zydus Cadila's Included Breast Cancer Drugs and Competitive Fall-Out

This report includes 247 companies (Incl. Active, Out of Business and M&A) plus their collaborators:

  • A&G Pharmaceutical
  • Abbott
  • Abiogen
  • Access
  • Adherex
  • Advanomics
  • Advaxis
  • AEgera
  • AEterna Zentaris
  • Affibody
  • Affimed Therapeutics
  • Alchemia
  • Alethia Biotherapeutics
  • Allos Therapeutics
  • Alnis Biosciences
  • AlphaVax
  • Alseres Pharmaceuticals
  • Amgen
  • AngioChem
  • Antisoma
  • Aphios
  • Ariad
  • ArQule
  • Array BioPharma
  • Ascend Therapeutics
  • Ascepion Pharmaceuticals
  • Astellas
  • Astex Pharmaceuticals
  • AstraZeneca
  • Attenuon
  • AVI BioPharma
  • Basilea Pharmaceutica
  • Bavarian Nordic
  • Bayer
  • Beta Pharma
  • Betagenon
  • Biogen Idec
  • BioMarin
  • Bionovo
  • BioSante
  • Biotecnol
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • BTG
  • Callisto Pharmaceuticals
  • Cancer Research Technology
  • Celgene
  • Cell Therapeutics
  • Celldex Therapeutics
  • Celltrion
  • Cel-Sci
  • Celsion
  • Celtic Pharma
  • Center of Molecular Immunology
  • Chemokine Therapeutics
  • Chiesi
  • Chong Kun Dang
  • CompleGen
  • Curis
  • Cyclacel
  • Cylene Pharmaceuticals
  • Cynvec
  • CytImmune Sciences
  • Cytokinetics
  • CytRx
  • Daiichi Sankyo
  • Dainippon Sumitomo Pharma
  • Debiopharm
  • Dendreon
  • Domainex
  • Dong-A
  • Dongkook Pharm
  • Douglas
  • ECI
  • Eisai
  • Elara Pharmaceuticals
  • ElexoPharm
  • Eli Lilly
  • Endoceutics
  • Enkam Pharmaceuticals
  • EntreMed
  • Enzon
  • Epeius Biotechnologies
  • EpiCept
  • Epizyme
  • Esperance Pharmaceuticals
  • Etubics
  • Eucodis
  • Exelixis
  • Expression Drug Designs
  • Formula Pharmaceuticals
  • Fresenius
  • Galectin Therapeutics
  • Galena Biopharma
  • Genentech
  • Generex
  • Genmab
  • Genta
  • GenVec
  • Geron
  • Gilead Sciences
  • GlaxoSmithKline
  • GlyTag
  • Got-a-Gene
  • Gradalis
  • Harbor BioSciences
  • Heidelberg Pharma
  • Hoffmann-La Roche
  • Hospira
  • Idera Pharmaceuticals
  • Immunocore
  • ImmunoGen
  • Immunomedics
  • ImmuPharma
  • Immutep
  • Incyte Corporation
  • Inex
  • Infinity Pharmaceuticals
  • Innate Pharma
  • InNexus Biotechnology
  • Inovio
  • Insmed
  • Insys Therapeutics
  • Intarcia Therapeutics
  • Intezyne Technologies
  • Intradigm
  • Introgen Therapeutics
  • Ipsen
  • Isis Pharmaceuticals
  • Jina Pharmaceuticals
  • Johnson & Johnson
  • Kiadis
  • Kinex
  • Kyowa Hakko Kirin
  • Leo
  • Ligand
  • Lorus Therapeutics
  • MacroGenics
  • Marillion Pharmaceuticals
  • Marina Biotech
  • Meda
  • Medarex
  • MediGene
  • MedImmune
  • Mediolanum
  • Menarini
  • Merck & Co
  • Merck KGaA
  • Merrimack
  • MetaMol Theranostics
  • Mologen
  • Nektar Therapeutics
  • Nemod Biotherapeutics
  • Neurocrine Biosciences
  • NexGenix Pharmaceuticals
  • Nidus Laboratories
  • NIH
  • Nimbus Discovery
  • Nippon Kayaku
  • Non-industrial source
  • Novartis
  • Novogen
  • Oasmia
  • OncoGenex Pharmaceuticals
  • Oncolix
  • OncoMune
  • Onconova
  • Oncothyreon
  • Oncozyme Pharma
  • Orion Pharma
  • OSI Pharmaceuticals
  • Oxford BioMedica
  • Pacific Biotech
  • Paladin Labs
  • PanaGin
  • Pantarhei Bioscience
  • Peregrine Pharmaceuticals
  • Pfizer
  • Pharmacyclics
  • PharmaGap
  • PharmaMar
  • Pharmexa
  • PheneX
  • Philogen
  • Pierre Fabre
  • Piramal
  • ProStrakan
  • PTC Therapeutics
  • R&R
  • Radient Pharmaceuticals
  • Raptor Pharmaceutical
  • Receptor BioLogix
  • Regeneron
  • Regulon
  • RESprotect
  • Rigel
  • Samyang
  • Sanofi
  • Santaris Pharma
  • Sareum
  • Savient Pharmaceuticals
  • Schering-Plough
  • SEEK
  • Selvita
  • Semafore Pharmaceuticals
  • Shenogen
  • Sigma-Tau
  • Sirnaomics
  • SRI International
  • Sun Pharma Advanced Research
  • Supratek Pharma
  • Synageva BioPharma
  • Synta Pharmaceuticals
  • Taiho
  • Taiwan Liposome Company
  • Takeda
  • Tapestry Pharmaceuticals
  • TapImmune
  • Targa Therapeutics
  • Tau Therapeutics
  • Taxolog
  • Telik
  • Teva
  • Thallion Pharmaceuticals
  • Therion Biologics
  • to-BBB
  • TopoTarget
  • Tragara Pharmaceuticals
  • Transgene
  • Trion Pharma
  • Vaccinex
  • Vaxon Biotech
  • Verastem
  • Vernalis
  • Vical
  • Vion Pharmaceuticals
  • VioQuest
  • ViroMed
  • ViroTarg
  • Wilex
  • Wyeth
  • Xerion
  • Xoma
  • Yakult Honsha
  • YM BioSciences
  • Zensun
  • Zydus Cadila

This report includes 470 breast cancer drugs. From Ceased to Marketed.

Some examples are:

  • abiraterone acetate
  • adecatumumab
  • aderbasib
  • AE-37
  • AEG-35156
  • afatinib
  • aflibercept
  • agatolimod
  • AMG-386
  • amonafide dihydrochloride
  • amonafide malate
  • amrubicin hydrochloride
  • anastrozole
  • Angiozyme
  • apricoxib
  • atrasentan
  • AUY-922
  • AVX-701
  • axitinib
  • AZD-4547
  • AZD-8931
  • bevacizumab
  • BEZ-235
  • BGT-226
  • BMS-690514
  • BMS-753493
  • BMS-754807
  • bortezomib
  • brivudine
  • BZL-101
  • Cabozantinib
  • canfosfamide hydrochloride
  • capecitabine
  • catumaxomab
  • cediranib
  • celecoxib
  • cetuximab
  • cilengitide
  • cixutumumab
  • CNF-2024
  • custirsen
  • dalotuzumab
  • dasatinib
  • daunorubicin
  • denosumab
  • dinaciclib
  • docetaxel
  • dovitinib lactate
  • doxifluridine
  • doxorubicin
  • E-75
  • elsamitrucin
  • endoxifen
  • eniluracil
  • entinostat
  • enzastaurin hydrochloride
  • epirubicin
  • erlotinib
  • ertumaxomab
  • estetrol
  • everolimus
  • exemestane
  • Exherin
  • F16-IL2
  • fadrozole
  • figitumumab
  • formestane
  • fulvestrant
  • ganitumab
  • gimatecan
  • glembatumumab vedotin
  • goserelin
  • GVAX
  • Her-2/Neu peptides
  • icotinib hydrochloride
  • idronoxil
  • imetelstat
  • IMP-321
  • INCB-028060
  • iniparib
  • ipilimumab
  • IPP-204106
  • irinotecan
  • irinotecan hydrochloride
  • irosustat
  • ispinesib mesylate
  • lapatinib ditosylate
  • lasofoxifene
  • letrozole
  • leucine-doxorubicin
  • leuprorelin
  • linifanib
  • LipoVIL12
  • lonafarnib
  • lonaprisan
  • LOR-2040
  • MetXia
  • milataxel
  • mitoxantrone
  • MKC-1
  • MM-111
  • MM-121
  • motesanib diphosphate
  • MVA-BN Her-2 vaccine
  • Nab-docetaxel
  • neratinib
  • NK-012
  • oblimersen sodium
  • olaparib
  • P276-00
  • paclitaxel
  • paclitaxel polyglumex
  • panobinostat
  • pazopanib hydrochloride
  • PD-0332991
  • pemetrexed disodium
  • perifosine
  • pertuzumab
  • pixantrone
  • pralatrexate
  • PTC-299
  • raloxifene hydrochloride
  • ramucirumab
  • Reximmune-C
  • Rexin-G
  • ridaforolimus
  • romidepsin
  • sagopilone
  • seliciclib
  • SN-38
  • sorafenib tosylate
  • SU-6668
  • talminogene laherparepvec
  • tamoxifen
  • tamoxifen, oral liquid
  • TAS-108
  • temsirolimus
  • Tenarad
  • TG-4010
  • tipifarnib
  • tivozanib
  • toremifene citrate
  • trastuzumab
  • trastuzumab emtansine
  • triciribine phosphate
  • trilostane
  • triptorelin pamoate
  • TroVax
  • TS-1
  • vandetanib
  • varlitinib
  • WX-671
  • XL-147
  • XL-647
  • XL-765
  • YM-155
  • zibotentan
Show More
Pricing